# GRO Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gro-biosciences

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.grobio.com
- Total disclosed funding: $58M
- Latest round: Series B (Jul 18, 2024)
- Investors on record: 11

## About

GRO Biosciences, Inc., based in the US, specializes in developing innovative protein therapeutics using its proprietary GRO platform to enhance therapeutic proteins through non-standard amino acids.Founded in 2016, GRO Biosciences, Inc. is headquartered in Cambridge, US, and focuses on the development of protein therapeutics. The company was co-founded by Dan Mandell and Marc Lajoie, who have backgrounds in biotechnology. Since its inception, GRO has raised a total of USD 27.44 mn through various funding rounds, with the most recent being a Series B round in July 2024, co-led by Atlas Venture and Access Industries, along with participation from returning investors. This funding has resulted in a current company valuation of USD 53.071 mn.GRO Biosciences specializes in innovative protein therapeutics, leveraging its GRO platform to provide access to a comprehensive array of non-standard amino acids (NSAAs). This platform significantly enhances the potency, immunogenicity, and stability of therapeutic proteins. One of its key products is ProGly™, which features pre-glycosylated amino acids designed for precise glycan composition control, addressing complex health issues like autoimmune disorders. The company primarily serves pharmaceutical and biotechnology firms in North America and Europe.GRO Biosciences generates revenue through B2B partnerships with pharmaceutical companies, focusing on the development and commercialization of novel protein therapeutics. Revenue comes from milestone payments, licensing fees, and royalties associated with the successful market introduction of therapeutics, particularly leveraging its ProGly™ product line.In July 2024, GRO Biosciences raised USD 27.44 mn in Series B funding to advance its lead program for treating refractory gout into clinical trials. The company plans to broaden its pipeline and enhance its genomically recoded organism platform to facilitate scalable manufacturing of therapeutics based on non-standard amino acids. This funding will support their initiatives for new product development and expansion into additional therapeutic markets.

## Funding rounds

- Series B, Jul 18, 2024, $27M — Atlas Venture, Access Industries, Innovation Endeavors, Redmile Group, Digitalis Ventures, Leaps by Bayer
- Series A, Nov 3, 2021, $25M — Innovation Endeavors, Redmile Group, Digitalis Ventures, Leaps by Bayer
- Seed, Mar 13, 2019, $3.8M — Innovation Endeavors, Wilson Sonsini Goodrich & Rosati, Rising Tide, Heritage Provider Network, Awaken Capital, Digitalis Ventures, Pillar
- Seed, Sep 28, 2017, $2.1M — Innovation Endeavors, Digitalis Ventures

## Investors

- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Seed, Series A, Series B
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Seed, Series A, Series B
- Wilson Sonsini Goodrich & Rosati — Seed
- Rising Tide — Seed
- Heritage Provider Network — Seed
- Awaken Capital (https://capitalatlas.ai/funds/awaken-capital) — Seed
- Pillar (https://capitalatlas.ai/funds/pillar) — Seed
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series A, Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B
- Access Industries (https://capitalatlas.ai/funds/access-industries) — Series B